Comparison of prostate-specific promoters and the use of PSP-Driven virotherapy for prostate cancer

Yi Lu, Yu Zhang, Guimin Chang, Jun Zhang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer deaths in men today. Although virus-based gene therapy is a promising strategy to combat advanced prostate cancer, its current effectiveness is limited partially due to inefficient cellular transduction in vivo. To overcome this obstacle, conditional oncolytic viruses (such as conditional replication adenovirus (CRAD)) are developed to specifically target prostate without (or with minimal) systemic toxicity due to viral self-replication. In this study, we have analyzed and compared three prostate-specific promoters (PSA, probasin, and MMTV LTR) for their specificity and activity both in vitro and in vivo. Both mice model with xenograft prostate tumor model and canine model were used. The best PSP was selected to construct a prostate-specific oncolytic adenovirus (CRAD) by controlling the adenoviral E1 region. The efficacy and specificity of CRAD on prostate cancer cells were examined in cell culture and animal models.

Original languageEnglish (US)
Article number624632
JournalBioMed Research International
Volume2013
DOIs
StatePublished - Mar 11 2013

Fingerprint

Adenoviridae
Prostate
Prostatic Neoplasms
Viruses
Oncolytic Viruses
Gene therapy
Second Primary Neoplasms
Cell culture
Heterografts
Genetic Therapy
Toxicity
Canidae
Tumors
Cause of Death
Neoplasms
Animals
Animal Models
Cell Culture Techniques
Cells
Primary Spontaneous Pneumothorax

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Comparison of prostate-specific promoters and the use of PSP-Driven virotherapy for prostate cancer. / Lu, Yi; Zhang, Yu; Chang, Guimin; Zhang, Jun.

In: BioMed Research International, Vol. 2013, 624632, 11.03.2013.

Research output: Contribution to journalArticle

@article{9af6325c4f28435e94477803c58526ff,
title = "Comparison of prostate-specific promoters and the use of PSP-Driven virotherapy for prostate cancer",
abstract = "Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer deaths in men today. Although virus-based gene therapy is a promising strategy to combat advanced prostate cancer, its current effectiveness is limited partially due to inefficient cellular transduction in vivo. To overcome this obstacle, conditional oncolytic viruses (such as conditional replication adenovirus (CRAD)) are developed to specifically target prostate without (or with minimal) systemic toxicity due to viral self-replication. In this study, we have analyzed and compared three prostate-specific promoters (PSA, probasin, and MMTV LTR) for their specificity and activity both in vitro and in vivo. Both mice model with xenograft prostate tumor model and canine model were used. The best PSP was selected to construct a prostate-specific oncolytic adenovirus (CRAD) by controlling the adenoviral E1 region. The efficacy and specificity of CRAD on prostate cancer cells were examined in cell culture and animal models.",
author = "Yi Lu and Yu Zhang and Guimin Chang and Jun Zhang",
year = "2013",
month = "3",
day = "11",
doi = "10.1155/2013/624632",
language = "English (US)",
volume = "2013",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Comparison of prostate-specific promoters and the use of PSP-Driven virotherapy for prostate cancer

AU - Lu, Yi

AU - Zhang, Yu

AU - Chang, Guimin

AU - Zhang, Jun

PY - 2013/3/11

Y1 - 2013/3/11

N2 - Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer deaths in men today. Although virus-based gene therapy is a promising strategy to combat advanced prostate cancer, its current effectiveness is limited partially due to inefficient cellular transduction in vivo. To overcome this obstacle, conditional oncolytic viruses (such as conditional replication adenovirus (CRAD)) are developed to specifically target prostate without (or with minimal) systemic toxicity due to viral self-replication. In this study, we have analyzed and compared three prostate-specific promoters (PSA, probasin, and MMTV LTR) for their specificity and activity both in vitro and in vivo. Both mice model with xenograft prostate tumor model and canine model were used. The best PSP was selected to construct a prostate-specific oncolytic adenovirus (CRAD) by controlling the adenoviral E1 region. The efficacy and specificity of CRAD on prostate cancer cells were examined in cell culture and animal models.

AB - Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer deaths in men today. Although virus-based gene therapy is a promising strategy to combat advanced prostate cancer, its current effectiveness is limited partially due to inefficient cellular transduction in vivo. To overcome this obstacle, conditional oncolytic viruses (such as conditional replication adenovirus (CRAD)) are developed to specifically target prostate without (or with minimal) systemic toxicity due to viral self-replication. In this study, we have analyzed and compared three prostate-specific promoters (PSA, probasin, and MMTV LTR) for their specificity and activity both in vitro and in vivo. Both mice model with xenograft prostate tumor model and canine model were used. The best PSP was selected to construct a prostate-specific oncolytic adenovirus (CRAD) by controlling the adenoviral E1 region. The efficacy and specificity of CRAD on prostate cancer cells were examined in cell culture and animal models.

UR - http://www.scopus.com/inward/record.url?scp=84874620695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874620695&partnerID=8YFLogxK

U2 - 10.1155/2013/624632

DO - 10.1155/2013/624632

M3 - Article

VL - 2013

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 624632

ER -